Brief Oral Communication -Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) X CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Results from an Ongoing Phase 1 Study
ESH eLearning, Faculty / Presenters,
336516
Brief Oral Communication - Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Updated Analysis of Griffin after 12 Months of Maintenance Therapy
ESH eLearning, Faculty / Presenters,
336499
Brief oral Communication: Cpi-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis patients: update of manifest Phase 2 study
ESH eLearning, Francesco Passamonti,
348310